Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Execs Flag Up More Brexit Regulatory Woes – And A Possible Solution

Executive Summary

Pharma executives painted a rather bleak picture of a UK regulatory system cast adrift by a hard Brexit, with problems likely in areas such as drug approvals, clinical trials and the role of the MHRA. One solution was proposed, however, to avoid the need for a free-standing UK approvals system for new drugs.


Related Content

Brexit Could Rob Industry Of Access To Markets Covered By 35 EU Free Trade Deals
Pharma Lauds Brexit ‘Breakthrough’ But Says Focus Now Must Be On Drug Regulation & Supply
EMA Explains How To Make Brexit-Related MA Changes, As Industry Bodies Urge Transition Period





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts